Cargando…
Update on systemic treatment in early triple negative breast cancer
Triple negative breast cancer (TNBC) is a heterogeneous disease representing about 15% of all breast cancers. TNBC are usually high-grade histological tumors, and are generally more aggressive and difficult to treat due to the lack of targeted therapies available, and chemotherapy remains the standa...
Autores principales: | Núñez Abad, Martín, Calabuig-Fariñas, Silvia, Lobo de Mena, Miriam, José Godes Sanz de Bremond, María, García González, Clara, Torres Martínez, Susana, García-García, José Ángel, Iranzo González-Cruz, Vega, Camps Herrero, Carlos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871289/ https://www.ncbi.nlm.nih.gov/pubmed/33613695 http://dx.doi.org/10.1177/1758835920986749 |
Ejemplares similares
-
Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
por: Núñez Abad, Martín, et al.
Publicado: (2022) -
Exosomal microRNAs in non-small cell lung cancer
por: Duréndez-Sáez, Elena, et al.
Publicado: (2021) -
MicroRNAs: Promising New Antiangiogenic Targets in Cancer
por: Gallach, Sandra, et al.
Publicado: (2014) -
NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
por: Sánchez‐Herrero, Estela, et al.
Publicado: (2021) -
Relation of Malnutrition and Nosocomical Infections in Cancer Patients in Hospital: An Observational Study
por: Muresan, Bianca Tabita, et al.
Publicado: (2022)